Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MTOR | P42345 | 2/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.97 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.97 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | HBB | P68871 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CDA | P32320 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytidine SCHEMBL27715166 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL339188 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL331331 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL67288 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL9043997 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL339189 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL27878729 | 0.99 | LMNA (0.95) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL28325598 | 0.99 | LMNA (0.95) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL23066241 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL17993618 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1283211-B1 | L-Nucleosides for the treatment of hepatitis B-virus and Epstein-barr virus | UNIV GEORGIA RES FOUND (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-0748330-B1 | L-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B-VIRUS AND EPSTEIN-BAR VIRUS | UNIV GEORGIA RES FOUND (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1283211-A2 | L-Nucleosides for the treatment of hepatitis B-virus and Epstein-barr virus | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2003-02-12 | — | — | EP | disclosed |
| US-5808040-A | VIRICIDES | YALE UNIVERSITY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5753789-A | Oligonucleotides containing L-nucleosides | YALE UNIVERSITY (US) | 1998-05-19 | — | — | US | disclosed |
| US-5587362-A | VIRICIDES FOR HEPATITIS VIRUS AND EPSTEIN-BAR VIRUS | UNIV. OF GA RESEARCH FOUNDATION (US) | 1996-12-24 | — | — | US | disclosed |
| US-5567688-A | ADMINISTERING SPECIFIED ENANTIOMORPH TO HUMAN INFECTED WITH HEPATITIS B VIRUS | UNIV. OF GA RESEARCH FOUNDATION (US) | 1996-10-22 | — | — | US | disclosed |
| US-5565438-A | L-nucleosides for the treatment of epstein-bar virus | UNIVERSITY OF GA RESEARCH FOUNDATION (US) | 1996-10-15 | — | — | US | disclosed |